Clinical Trials Logo

Hepatitis, Autoimmune clinical trials

View clinical trials related to Hepatitis, Autoimmune.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03593460 Withdrawn - Clinical trials for Hepatitis, Autoimmune

Phase II AutoImmune Hepatitis

Start date: January 1, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase IIa open label adaptive design dose finding study in male and female patients with autoimmune hepatitis (AIH) with compensated liver function currently under standard of care. The purpose of this study is to evaluate the sPIF dose that normalizes and maintains the serum ALT when given for 14 doses. Autoimmune Hepatitis is disease where the patient's immune system produces an inappropriate immune response against their own liver. PreImplantation factor (PIF) is a substance that is secreted by viable fetuses during pregnancy. PIF initiates both maternal tolerance preventing the loss/rejection of the fetus. Synthetic PIF (sPIF) successfully translates PIF endogenous properties to pregnant and non-pregnant immune disorders. sPIF was found to be effective in preclinical models of autoimmunity and transplantation. Specifically, sPIF protected the liver against immune attack.

NCT ID: NCT02878863 Withdrawn - Clinical trials for Hepatitis, Autoimmune

Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis

Start date: August 2016
Phase: Phase 3
Study type: Interventional

An open-label,prospective, randomized pilot study to evaluate the efficacy, safety and tolerability of paeoniflorin, for the treatment of autoimmune hepatitis (AIH) with mild necroinflammatory activity on liver biopsy.

NCT ID: NCT00587119 Withdrawn - Clinical trials for Primary Biliary Cirrhosis

Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis

PBC
Start date: December 2007
Phase: N/A
Study type: Interventional

The purpose of the study is to find out the effects Budesonide, 9 mg daily for one year, has on patients with Primary Biliary Cirrhosis with features of autoimmune hepatitis.